CD19 Antibody (CB19) [Allophycocyanin/Cy7]

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-25196APCCY7

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP2-25196APCCY7
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Validated by

Biological Validation

Species Reactivity

Human, Mouse

Applications

CyTOF-ready, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, In vitro assay, Western Blot

Label

Allophycocyanin/Cy7 (Excitation = 650;755 nm, Emission = 767 nm)

Antibody Source

Monoclonal Mouse IgG1 Clone # CB19

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

View all CD19 Antibodies »

Product Specifications

Immunogen

Intact normal human B cell cells were used as immunogen to generate the CB19 clone.

Epitope

The exact CD19 epitope recognized by the antibody has not been mapped and is unknown.

Reactivity Notes

Mouse reactivity reported in scientific literature (PMID: 27532872).

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Scientific Data Images for CD19 Antibody (CB19) [Allophycocyanin/Cy7]

CD19 Antibody (CB19) [Allophycocyanin/Cy7]

Flow Cytometry: Mouse Monoclonal CD19 Antibody (CB19) [Allophycocyanin/Cy7] [NBP2-25196APCCY7] -

Flow Cytometry: Mouse Monoclonal CD19 Antibody (CB19) [Allophycocyanin/Cy7] [NBP2-25196APCCY7] - Detection of human CD19 on the Raji cell line. Cells were treated with 10 nM of the human CD19 APC/Cy7-conjugated antibody (BLUE) for 30 minutes on ice or mouse IgG1 APC/Cy7-conjugated isotype control antibody (RED). Image from a verified customer review.
Product Image: CD19 Antibody (CB19) [Allophycocyanin/Cy7] [NBP2-25196APCCY7] - Vial of APC/Cy7 conjugated antibody. APC/Cy7 is optimally excited at 652 nm by the Red laser (633 or 640 nm) and has an emission maximum of 775 nm.

Applications for CD19 Antibody (CB19) [Allophycocyanin/Cy7]

Application
Recommended Usage

CyTOF-ready

Optimal dilutions of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Immunocytochemistry/ Immunofluorescence

Optimal dilutions of this antibody should be experimentally determined.

In vitro assay

Optimal dilutions of this antibody should be experimentally determined.

Western Blot

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Reviewed Applications

Read 1 review rated 5 using NBP2-25196APCCY7 in the following applications:

Formulation, Preparation, and Storage

Purification

Protein G purified

Formulation

PBS

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark. Do not freeze.

Background: CD19

CD19 (Cluster of Differentiation 19), also known as B-lymphocyte surface antigen B4, is a type 1 transmembrane glycoprotein belonging to immunoglobulin (Ig) subfamily that serves as a biomarker for normal and neoplastic B cells (1,2). CD19 is a co-receptor for the B cell receptor (BCR) signaling complex and has a critical role in regulating B cell signaling and immune response (1,2). The CD19 protein contains an extracellular N-terminus containing two C2 Ig-like domains separated by a helical non-Ig domain, a single pass transmembrane domain, and a highly conserved cytoplasmic C-terminal domain (1,2). The human CD19 protein, encoded by the CD19 gene located on chromosome 16p11.2, is 556 amino acids (aa) in length with a calculated theoretical molecular weight (MW) of 61 kDa and an observed molecular weight of 95 kDa (1-3). CD19 associates with other molecules - CD21, CD81, and CD225 - to form the BCR co-complex, also called the CD19 complex, through CD21 binding to the complement C3d complex (1-3). Complement C3d bridges the BCR with the CD19 complex into lipid rafts of the plasma membrane (1-3). CD19 is capable of modulating B cell development through both BCR-dependent and -independent signaling (1-3). Upon BCR activation, the tyrosine residues of CD19's cytoplasmic tail recruits multiple kinases including Lyn, Vav, and PI3K, amplifying BCR-mediated immune signaling and B cell activation (1-3).

Considering the role of CD19 in BCR signaling and its expression in development from pre-B cells through plasma cells, it is understandable that CD19 dysfunction and abnormal expression is associated with numerous B cell malignancies and autoimmune disorders (1-5). CD19 expression is typically observed at relatively normal levels in B cell acute lymphoblastic leukemia (B-ALL) and chronic lymphoblastic leukemia (CLL) but is often reduced other types of lymphoma including diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) (1,2). On the other hand, CD19 expression is typically increased in autoimmune disorders such as systemic sclerosis (SSc) and multiple sclerosis (MS) as modeled by experimental autoimmune encephalomyelitis (EAE) (2). CD19 has become a therapeutic molecular target for the treatment of B cell lymphomas and autoimmune disorders using monoclonal antibodies (mAbs), bi-specific T cell engaging (BiTE) antibodies, and CD19-specific chimeric antigen receptor (CAR) T cells (1,2,4-6). Although anti-CD19 CAR T cell therapy has become the standard for the treatment of B cell malignancies, patients may experience relapse due to resistance mechanisms (6). Strategies to improve efficacy and limit relapse include combination of CAR T cell therapy with immune checkpoint inhibitors like anti-PD-1 (4,6).

References

1. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1(1):36. https://doi.org/10.1186/2162-3619-1-36

2. Li X, Ding Y, Zi M, et al. CD19, from bench to bedside. Immunol Lett. 2017;183:86-95. https://doi.org/10.1016/j.imlet.2017.01.010

3. Wentink MWJ, van Zelm MC, van Dongen JJM, Warnatz K, van der Burg M. Deficiencies in the CD19 complex. Clin Immunol. 2018;195:82-87. https://doi.org/10.1016/j.clim.2018.07.017

4. Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J Clin Invest. 2020;130(4):1586-1594. https://doi.org/10.1172/JCI129208

5. Penack O, Koenecke C. Complications after CD19+ CAR T-Cell Therapy. Cancers (Basel). 2020;12(11):3445. https://doi.org/10.3390/cancers12113445

6. Bouziana S, Bouzianas D. Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy. Crit Rev Oncol Hematol. 2021;157:103096. https://doi.org/10.1016/j.critrevonc.2020.103096

Alternate Names

CD19, CVID3, Leu-12

Gene Symbol

CD19

Additional CD19 Products

Product Documents for CD19 Antibody (CB19) [Allophycocyanin/Cy7]

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for CD19 Antibody (CB19) [Allophycocyanin/Cy7]

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.